XCath, a medical device company that is pioneering neuro-endovascular surgical robotics, part owned by Crescent Enterprises, announced today that it has secured $30 million in Series C funding, bringing the total raised since the company’s inception to $92 million. The latest funds will support
Crescent Enterprises
XCath, a medical device company dedicated to pioneering neuro-endovascular surgical robotics, and Crescent Enterprises, the founding and largest shareholder of XCath, have announced the successful first-in-human use of XCath’s EVR robotic system to treat three patients with complex brain aneurysms. The landmark procedures were performed at The Panama Clinic in Panama City,
CE-Ventures, the corporate venture capital platform of Crescent Enterprises, today announced its participation in the $7.7 million Series A funding round for India-based, research and development-led speciality chemicals company, Distil. Distil’s fundraise was led by CE-Ventures and Singapore-based Jungle Ventures with participation from strategic investors Rubamin, PI












